Guiding principles in the design of ligand-targeted nanomedicines

Nanomedicine

Volumn 9, Issue 2, 2014, Pages 313-330

  Wang, Bingbing ^a   Galliford, Chris V ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Diagnostic imaging agent; Intracellular delivery; Ligand targeted drug; Nanomedicine; Targeted nanoparticle

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; IMATINIB; LIGAND; MACROGOL; NANOCARRIER; NANOPARTICLE; POLYOL; POLYSACCHARIDE; SMALL INTERFERING RNA; VINCA ALKALOID; VINTAFOLIDE;

ADSORPTION; ANTIBODY PRODUCTION; B CELL LYMPHOMA; CELL SURFACE; CELL TYPE; CIRCULATION TIME; CYTOKINE RELEASE; DERIVATIZATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; HYDROPHILICITY; INFLAMMATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; MOLECULAR IMAGING; NANOMEDICINE; NEPHROTOXICITY; NONHUMAN; PH; PHYSICAL CHEMISTRY; PLASMID; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; STATIC ELECTRICITY; SURFACE CHARGE;

DRUG DESIGN; LIGANDS; NANOMEDICINE;

EID: 84896712836     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.175     Document Type: Review

References (224)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 349(15), 1451-1464 (2003).
2. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin Chem. Biol. 13(3), 256-262 (2009).
3. Lorusso PM, Edelman MJ, Bever SL et al. Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors. J. Clin. Oncol. 30(32), 4011-4016 (2012).
4. Kularatne SA, Wang K, Santhapuram HK, Low PS. Prostate-specific membrane ant igen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharm. 6(3), 780-789 (2009).
5. Thomas M, Kularatne SA, Qi L et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci. 1175, 32-39 (2009).
6. Zou M, Zhang L, Xie Y, Xu W. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature. Anticancer Agents Med. Chem. 12(3), 239-246 (2012).
7. Goff RD, Thorson JS. Assessment of chemoselective neoglycosylation methods using chlorambucil as a model. J. Med. Chem. 53(22), 8129-8139 (2010).
8. Ciuleanu TE, Pavlovsky AV, Bodokyg et al. A randomised Phase III trial of glufosfamide compared wit h best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur. J. Cancer 45(9), 1589-1596 (2009).
9. Kurzrock R, Gabrail N, Chandhasin C et al. Safet y, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11(2), 308-316 (2012).
10. Roosenburg S, Laverman P, Van Delft FL, Boerman OC. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 41(5), 1049-1058 (2011).
11. Xu L, Josan JS, Vagner J et al. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc. Natl Acad. Sci. USA 109(52), 21295-21300 (2012).
12. Zhang H, Abiraj K, Thorek DL et al. Evolution of bombesin conjugates for targeted PET imaging of tumors. PLoS ONE 7(9), e44046 (2012).
13. Zhou Z, Wagh NK, Ogbomo SM et al. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J. Nucl. Med. 54(9), 1605-1612 (2013).
14. Yu B, Mao Y, Bai LY et al. Targeted nanoparticle delivery ov ercomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121(1), 136-147 (2013).
15. Mccormack W, Oshima M, Tan P, Jenkins B. Toll-like receptor 2: Therapeutic target for gastric carcinogenesis. Oncotarget 3(11), 1260-1261 (2012).
16. Li K, Lv XX, Hua F et al. Targeting acute myeloid leukemia wit h a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Int. J. Cancer 134(3), 692-702 (2013).
17. Tafreshi NK, Silva A, Estrella VC et al. In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol. Pharm. 10(8), 3175-3185 (2013).
18. Tafreshi NK, Huang X, Moberg VE et al. Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) Specific ligand. Bioconjug. Chem. 23(12), 2451-2459 (2012).
19. Dong C, Liu Z, Wang F. Peptide-based radiopharmaceuticals for targeted tumor therapy. Curr. Med. Chem. 21(1), 139-152 (2013).
20. Barkey NM, Tafreshi NK, Josan JS et al. Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. J. Med. Chem. 54(23), 8078-8084 (2011).
21. Barkey NM, Preihs C, Cornnell HH et al. Development and in vivo quantitative magnetic resonance imaging of polymer micelles targeted to the melanocortin 1 receptor. J. Med. Chem. 56(16), 6330-6338 (2013).
22. Krebs LJ, Wang X, Pudavar HE et al. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Cancer Res. 60(15), 4194-4199 (2000).
23. Su Z, Shi Y, Xiao Y et al. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization. Int. J. Pharm. 447(1-2), 281-292 (2013).
24. Starkey JR, Pascucci EM, Drobizhev MA, Elliott A, Rebane AK. Vascular targeting to the SST2 receptor improves the th erapeutic response to near-IR two-photon activated PDT for deep-tissue cancer treatment. Biochim. Biophys. Acta 10(603), 7 (2013).
25. Van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, Van Gaal EV. L igand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv. Drug Deliv. Rev. 65(10), 1284-1298 (2013).
26. Tros De Ilarduya C, Duzgunes N. Delivery of therapeutic nucle ic acids via transferrin and transferrin receptors: Lipoplexes and other carriers. Expert Opin Drug Deliv. 10(11), 1583-1591 (2013).
27. Tavano L, Muzzalupo R, Mauro L, Pellegrino M, Ando S, Picci N. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy. Langmuir 29(41), 12638-12646 (2013).
28. Nam JP, Park SC, Kim TH et al. Enc apsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. Int. J. Pharm. 457(1), 124-135 (2013).
29. Usami Y, Ishida K, Sato Set al. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int. J. Cancer 133(3), 568-578 (2013).
30. Gokhale M, Thakur A, Rinaldi F. Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev. Ind. Pharm. 39(9), 1315-1327 (2013).
31. Reddy JA, Dorton R, Dawson A et al. In vivo structural activity and optimization studies of folate-tubulysin conjugates. Mol. Pharm. 6(5), 1518-1525 (2009).
32. Guaragna A, Chiaviello A, Paolella C, D?Alon zo D, Palumbo G, Palumbo G. Synthesis and evaluation of folate-based chlorambucil delivery systems for tumor-targeted chemotherapy. Bioconjug. Chem. 23(1), 84-96 (2011).
33. Pinhassi RI, Assaraf YG, Farber Set al. Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules 11 (1), 294-303 (2010).
34. Xie M, Xu Y, Liu J, Zhang T, Zhang H. Preparation and characterization of folate targeting magnetic nanomedicine loaded with cisplatin. J. Nanomater. 2012, 921034 (2012).
35. Leamon CP, Reddy JA, Vlahov IR et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharm. 4(5), 659-667 (2007).
36. Amato RJ, Shetty A, Lu Y, Ellis R, Low PS. A Phase I study of folate immune therapy (ec90 vaccine administered with GPI-0100 adjuvant followed by ec17) in patients with renal cell carcinoma. J. Immunother. 36(4) , 268-275 (2013).
37. Leamon P, Lovejoy C, Nguyen B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers. Med. 6, 113-125 (2013).
38. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 14(3), 154-169 (2008).
39. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr. Opin Chem. Biol. 14(4), 529-537 (2010).
40. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat. Rev. Cancer 12(4), 278-287 (2012).
41. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov. 5(2), 147-159 (2006).
42. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev. 65(1), 36-48 (2013).
43. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv. 6(3), 285-304 (2009).
44. Sawant RR, Jhaveri AM, Koshkaryev A, Qureshi F, Torchilin VP. The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy. J. Drug Target. 21(7), 630-638 (2013).
45. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: Principles and practice. Br. J. Cancer 99(3), 392-397 (2008).
46. Mohanty C, Das M, Kanwar JR, Sahoo SK. Receptor mediated tumor targeting: An emerging approach for cancer therapy. Curr. Drug Deliv. 8(1), 45-58 (2011).
47. Lopez-Davila V, Seifalian AM, Loizidou M. Organic nanocarriers for cancer drug delivery. Curr. Opin Pharmacol. 12(4), 414-419 (2012).
48. Trapani G, Denora N, Trapani A, Laquintana V. Recent advances in ligand targeted therapy. J. Drug Target. 20(1), 1-22 (2012).
49. Mozafari MR, Pardakhty A, Azarmi S, Jazayeri JA, Nokhodchi A, Omri A. Role of nanocarrier systems in cancer nanotherapy. J. Liposome Res. 19(4), 310-321 (2009).
50. Choi HS, Liu W, Liu F et al. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 5(1), 42-47 (2010).
51. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
52. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol. Res. 62(2), 90-99 (2010).
53. Barenholz Y. Doxil-The first FDA-approved nano-drug: Lessons learned. J. Control. Release 160, 117-134 (2012).
54. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therap eutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008).
55. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211-1217 (2006).
56. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1-16 (2012).
57. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: Transport barriers and strategies. Annu. Rev. Biomed. Eng. 2(1), 281-298 (2011).
58. Sheng Y, Liu C, Yuan Y et al. Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials 30(12), 2340-2348 (2009).
59. Khandare J, Calderon M, Dagia NM, Haag R. Multifunctional dendritic polymers in nanomedicine: Opportunities and challenges. Chem. Soc. Rev. 41(7), 2824-2848 (2012).
60. Kidane A, Bhatt PP. Recent advances in small molecule drug delivery. Curr. Opin Chem. Biol. 9(4), 347-351 (2005).
61. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J. Control. Release 153(3), 198-205 (2011).
62. Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake Trends Biotechnol. 26(10), 552-558 (2008).
63. Iijima M, Kamiya H. Surface modification for improving the stability of nanoparticles in liquid Media. KONA Powder Part. J. (27), 119-129 (2009).
64. Boyer C, Teo J, Phillips P et al. Effective delivery of SIRNA into cancer cells and tumors using well-defined biodegradable cationic star polymers. Mol. Pharm. 10(6), 2435-2444 (2013).
65. Kango S, Kalia S, Celli A, Njuguna J, Habibi Y, Kumar R. Surface modification of inorganic nanoparticles for development of organic-ino rganic nanocomposites-A review. Prog. Polym. Sci. 38(8), 1232-1261 (2013).
66. Liu Y, Li W, Lao F et al. Intracellular dynamics of cationic and anionic polystyrene nanoparticles without direct interaction with mitotic spindle and chromosomes. Biomaterials 32(32), 8291-8303 (2011).
67. Rao DA, Forrest ML, Alani AW, Kwon GS, Robinson JR. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J. Pharm. Sci. 99(4), 2018-2031 (2010).
68. Porter CJ. Drug delivery to the lymphatic system. Crit. Rev. Ther. Drug Carrier Syst. 14(4), 333-393 (1997).
69. Elsabahy M, Shrestha R, Clark C, Taylor S, Leonard J, Wooley KL. Multifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of SIRNA and paclitaxel. Nano Lett. 13(5), 2172-2181 (2013).
70. Klauser RJ, Raake W, Meinetsberger E, Zeiller P. Antithrombotic and anticoagulant properties of synthetic polyanions: Sulfated bis-aldonic acid amides. J. Pharmacol. Exp. Ther. 259(1), 8-14 (1991).
71. Kannemeier C, Shibamiya A, Nakazawa F et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl Acad. Sci. USA 104(15), 6388-6393 (2007).
72. Mazumder MA, Umar Y, Ali SA. Synthesis and solution properties of a new poly(electrolyte-zwitterion). Polymer 45(1), 125-132 (2004).
73. Lowe AB, Mccormick CL. Synthesis and solution properties of zwitterionic polymers. Chem. Rev. 102(11), 4177-4190 (2002).
74. Dunn SE, Brindley A, Davis SS, Davies MC, Illum L. Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution. Pharm. Res. 11(7), 1016-1022 (1994).
75. Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano 7(4), 2935-2947 (2013).
76. Stefanick JF, Ashley JD, Bilgicer B. Enhanced cellular uptake of peptide-targeted nanoparticles through increased peptide hydrophilicity and optimized ethylene glycol peptide-linker length. ACS Nano 7(9), 8115-8127 (2013).
77. Armstrong JK, Hempel G, Koling Set al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leuk emia patients. Cancer 110(1), 103-111 (2007).
78. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibod ies. Cell. Mol. Biol. Lett. 10(1), 37-47 (2005).
79. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEG ylated liposomes. J. Control. Release 119(2), 236-244 (2007).
80. Hatakeyama H, Akita H, Harashima H. The polyethyleneglycol dilemma: Advantage and disadvantage of PEGylation of liposomes for sys temic genes and nucleic acids delivery to tumors. Biol. Pharm. Bull. 36(6), 892-899 (2013).
81. Bernardos A, Mondragon L, Aznar E et al. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with ?saccharides?. ACS Nano 4(11), 6353-6368 (2010).
82. Fallarini S, Paoletti T, Battaglini CO et al. Factors affecting T cell responses induced by fully synthetic glyco-gold-nanoparticles. Nanoscale 5(1), 390-400 (2013).
83. Hanini A, Schmitt A, Kacem K, Chau F, Ammar S, Gavard J. Evaluation of iron oxide nanoparticle biocomp atibility. Int. J. Nanomedicine 6, 787-794 (2011).
84. Li H, Jo JK, Zhang LD, Ha CS, Suh H, Kim I. Hyperbranched polyglycidol assisted green synthetic protocols for the preparation of multifunctional metal nanoparticles. Langmuir 26, 18442-18453 (2010).
85. Ishak RA, Awad GA, Zaki NM, El-Shamy Ael H, Mortada ND. A comparative study of chitosan shielding effect on nano-carriers hydrophilicity and biodistribution. Carbohydr. Polym. 94(1), 669-676 (2013).
86. Sansone F, Casnati A. Multivalent glycocalixarenes for recognition of biological macromolecules: Glycocalyx mimics capable of multitasking. Chem. Soc. Rev. 42(11), 4623-4639 (2013).
87. Stockert RJ, Haimes HB, Morell AG et al. Endocytosis of asialoglycoprotein-enzyme conjugates by hepatocytes. Lab. I nvest. 43(6), 556-563 (1980).
88. Shen J, Chelvam V, Cresswell G, Low PS. Use of folate-conjugated imaging agents to target alternatively activated macrophages in a murine model of asthma. Mol. Pharm. 10(5), 1918-1927 (2013).
89. Jacob GS, Kirmaier C, Abbas SZ et al. Binding of sialyl Lewis X to E-selectin as measured by fluorescence polarization. Biochemistry 34(4), 1210-1217 (1995).
90. Matsuura N , Narita T, Hiraiwa N et al. Gene expression of fucosyl-and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer. Int. J. Oncol. 12(5), 1157-1164 (1998).
91. Van Der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 14(3), 201-207 (2001).
92. Dienst A, Grunow A, Unruh Met al. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J. Natl Cancer Inst. 97(10), 733-747 (2005).
93. aumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: Animal models of the angiogenic switch. Cell Cycle 5(16), 1779-1787 (2006).
94. Zhang K, Waxman DJ. Impacto f tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model. Mol. Cancer Ther. 12(5), 787-798 (2013).
95. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148(2), 135-146 (2010).
96. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H. Macromolecular therapeutics: Advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 42(13), 1089-1105 (2003).
97. Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: Impact on receptor-mediated drug delivery. Mol. Pharmacol. 66(6), 1406-1414 (2004).
98. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9, 1909-1915 (2009).
99. Stylianopoulos T, Wong C, Bawendi MG, Jain RK, Fukumura D. Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol. 508, 109-130 (2012).
100. Wong C, Stylianopoulos T, Cui J et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108(6), 2426-2431 (2011).
101. Van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a ? binding site barrier.?Cancer Res. 51(18), 4776-4784 (1991).
102. Weinstein JN, Van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: Micropharmacology and the ? binding site barrier.?Cancer Res. 52(9 Suppl.), S2747-S2751 (1992).
103. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J. Nucl. Med. 31(7), 1191-1198 (1990).
104. Kostarelos K, Emfietzoglou D, Papakostas A, Yang WH, Ballangrud A, Sgouros G. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int. J. Cancer 112(4), 713-721 (2004).
105. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm. 7(4), 1195-1208 (2010).
106. Juweid M, Neumann R, Paik C et al. Micropharmacology of monoclonal antibodies in solid tumors: Direct experimental evidence for a binding site barrier. Cancer Res. 52(19), 5144-5153 (1992).
107. Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol. 25(10), 1165-1170 (2007).
108. Gabizon A, Cat ane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54(4), 987-992 (1994).
109. Von Maltzahn G, Park JH, Agrawal A et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 69(9), 3892-3900 (2009).
110. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: Challenges, solutions and future prospects. Curr. Pharm. Des. 16(21), 2298-2307 (2010).
111. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001).
112. Brain JD, Molina RM, Decamp MM, Warner AE. Pulmonary intravascular macrophages: Their contribution to the mononuclear phagocyte system in 13 species. Am. J. Physiol. 276(1 Pt 1), L146-L154 (1999).
113. Ogawara K, Furumoto K, Takakura Y, Has hida M, Higaki K, Kimura T. Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J. Control. Release 77(3), 191-198 (2001).
114. Yamaoka T, Tabata Y, Ikada Y. Blood clearance and organ distribution of intravenously administered polystyrene microspheres of different sizes. J. Bioact. Compat. Pol. 8(3), 220-235 (1993).
115. Simon BH, Ando HY, Gupta PK. Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. J. Pharm. Sci. 84(10), 1249-1253 (1995).
116. Treuel L, Jiang X, Nienhaus GU. New views on cellular uptake and trafficking of manufactured nanoparticles. J. R. Soc. Interface 10(82), 20120939 (2013).
117. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J. Control. Release 145(3), 182-195 (2010).
118. Hon NK, Shaposhnik Z, Diebold ED, Tamanoi F, Jalali B. Tailoring the biodegradability of porous silicon nanoparticles. J. Biomed. Mater. Res. A 100A(12), 3416-3421 (2012).
119. Vlashi E, Kelderhouse LE, Sturgis JE, Low PS. Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors. ACS Nano 7(10), 8573-8582 (2013).
120. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. Size-dependent endocytosis of nanoparticles. Adv. Mater. 21, 419-424 (2009).
121. Iversen T-G, Skotland T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studie s. Nano Today 6(2), 176-185 (2011).
122. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J. Control. Release 118(1), 7-17 (2007).
123. Goldberg MS, Hook SS, Wang AZ et al. Biotargeted nanomedicines for cancer: Six tenets before you begin. Nanomedicine 8(2), 299-308 (2013).
124. Yue C, Liu P, Zheng Met al. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials 34(28), 6853-6861 (2013).
125. Liu P, Yue C, Shi B et al. Dextran based sensitive theranostic nanoparticles for near-infrared imaging and photothermal therapy in vitro. Chem. Commun. 49(55), 6143-6145 (2013).
126. Wadajkar AS, Menon JU, Kadapure T, Tran RT, Yang J, Nguyen KT. Design and application of magnetic-based theranostic nanoparticle systems. Recent Pat. Biomed. Eng. 6(1), 47-57 (2013).
127. Gnanasammandhan MK, Bansal A, Zhang Y. Light-activated endosomal escape using upconversion nanoparticles for enhanced delivery of drugs. Proc. SPIE 8594, 85940B (2013).
128. Shrestha R, Elsabahy M, Florez-Malaver S, Samarajeewa S, Wooley KL. Endosomal escape and SIRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities. Biomaterials 33 (33), 8557-8568 (2012).
129. Wang M, Li X, Ma Y, Gu H. Endosomal escape kinetics of mesoporous silica-based system for efficient SIRNA delivery. Int. J. Pharm. 448(1), 51-57 (2013).
130. Tian W-D, Ma Y-Q. Insights into the endosomal escape mechanism via investigation of dendrimer-membrane interactions. Soft Matter 8(23), 6378-6384 (2012).
131. Adjei IM, Peetla C, Labhasetwar V. Heterogeneity in nanoparticles influences biodistribution and targeting. Nanomedicine 8, 1-12 (2013).
132. Kotov NA, Stellacci F. Frontiers in nanoparticle research: Toward greater complexity of structure and function of nanomaterials. Adv. Mater. 20(22), 4221-4222 (2008).
133. Chu KS, Hasan W, Rawal Set al. Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 9(5), 686-693 (2013).
134. Doshi N, Mitragotri S. Designer biomaterials for nanomedicine. Adv. Funct. Mater. 19(24), 3843-3854 (2009).
135. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat. Mater. 8(1), 15-23 (2009).
136. Gratton SE, Ropp PA, Pohlhaus PD et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105(33), 11613-11618 (2008).
137. Geng Y, Dalhaimer P, Cai Set al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249-255 (2007).
138. Park J-H , Von Maltzahn G, Zhang L et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mat. 20(9), 1630-1635 (2008).
139. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
140. Beatty K, Winkelman C, Bokar JA, Mazanec P. Advances in oncology care: Targeted therapies. AACN Adv. Crit. Care 22(4), 323-334 (2011).
141. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2(10), 750-763 (2002).
142. Strebhardt K, Ullrich A. Paul Ehrlich?s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8(6), 473-480 (2008).
143. Kularatne SA, Venkatesh C, Santhapuram HK et al. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs. J. Med. Chem. 53(21), 7767-7777 (2010).
144. Xia W, Low PS. Folate-targeted therapies for cancer. J. Med. Chem. 53(19), 6811-6824 (2010).
145. Silpe JE, Sumit M, Thomas TP et al. Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles. ACS Chem. Biol. 8(9), 2063-2071 (2013).
146. Simnick AJ, Valencia CA, Liu R, Chilkoti A. Morphing low-affinity ligands into high-avidity nanoparticles by thermally triggered self-assembly of a genetically encoded polymer. ACS Nano 4(4), 2217-2227 (2010).
147. Zern BJ, Chacko AM, Liu J et al. Reduction of nanoparticle avidity enhances the selectivity of vascular targeting and PET detection of pulmonary inflammation. ACS Nano 7(3), 2461-2469 (2013).
148. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak Holl MM. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platfor m. Chem. Biol. 14(1), 107-115 (2007).
149. Lameignere E, Malinovska L, Slavikova Met al. Structural basis for mannose recognition by a lectin from opportunistic bacteria Burkholderia cenocepacia. Biochem. J. 411(2), 307-318 (2008).
150. Marradi M, Chiodo F, Garcia I, Penades S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem. Soc. Rev. 42(11), 4728-4745 (2013).
151. Siheln?kov? L, Tvaro? ka I. Step by step towards understanding gold glyconanoparticles as elements of the nanoworld. Chem. Pap. 61(4), 237-255 (2007).
152. Reynolds M, Marradi M, Imberty A, Penades S, Perez S. Influence of ligand presentation density on the molecular recognition of mannose-functionalised glyconanoparticles by bacterial lectin BC2L-A. Glycoconjug. J. 30, 747-757 (2013).
153. Stella B, Arpicco S, Peracchia MT et al. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89(11), 1452-1464 (2000).
154. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: Evolution of technologies and bench to bedside translation. Acc. Chem. Res. 44(10), 1123-1134 (2011).
155. Weerakkody D, Moshnikova A, Thakur MS et al. Family of pH (low) insertion peptides for tumor targeting. Proc. Natl Acad. Sci. USA 110(15), 5834-5839 (2013).
156. Yao L, Daniels J, Moshnikova A et al. pHLIP peptide targets nanogold particles to tumors. Proc. Natl Acad. Sci. USA 110(2), 465-470 (2013).
157. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56(8), 1177-1192 (2004).
158. Gabizon A, Tzemach D, Gorin J et al. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother. Pharmacol. 66(1), 43-52 (2010).
159. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl Acad. Sci. USA 103(37), 13872-13877 (2006).
160. Ho K, Lapitsky Y, Shi M, Shoichet MS. Tunable immunonanoparticle binding to cancer cells: Thermodynamic analysis of targeted drug delivery vehicles. Soft Matter 5(5), 1074-1080 (2009).
161. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J. Biol. Chem. 276(17), 14385-14392 (2001).
162. Gabizon A, Horowitz AT, Goren D et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: In v itro studies. Bioconjug. Chem. 10(2), 289-298 (1999).
163. Reddy JA, Dean D, Kennedy MD, Low PS. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. J. P harm. Sci. 88(11), 1112-1118 (1999).
164. Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. J. Control. Release 64(1-3), 27-37 (2000).
165. Saul JM, Annapragada A, Natarajan JV, Bellamkonda RV. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Release 92(1-2), 49-67 (2003).
166. Liu J, Weller GE, Zern B et al. Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proc. Natl Acad. Sci. USA 107(38), 16530-16535 (2010).
167. Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine 9(2), 194-201 (2013).
168. Lee H, Lytton-Jean AK, Chen Y et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo SIRNA delivery. Nat. Nanotechnol. 7(6), 389-393 (2012).
169. Martinez-Veracoechea FJ, Frenkel D. Designing super selectivity in multivalent nano-particle binding. Proc. Natl Acad. Sci. USA 108(27), 10963-10968 (2011).
170. Saul JM, Annapragada AV, Bellamkonda RV. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 114(3), 277-287 (2006).
171. Ying X, Wen H, Lu WL et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control. Release 141(2), 183-192 (2010).
172. Kluza E, Van Der Schaft DW, Hautvast PA et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 10(1), 52-58 (2010).
173. Li X, Zhou H, Yang L et al. Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles. Biomaterials 32(10), 2540-2545 (2011).
174. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822 (1990).
175. Cohen BA, Colas P, Brent R. An artificial cell-cycle inhibitor isolated from a combinatorial library. Proc. Natl Acad. Sci. USA 95(24), 14272-14277 (1998).
176. Hussain M, Gera N, Hill AB, Rao BM. Scaffold diversification enhances effectiveness of a superlibrary of hyperthermophilic proteins. ACS Synth. Biol. 2(1), 6-13 (2012).
177. Schwimmer LJ, Huang B, Giang H et al. Discovery of diverse and functional antibodies from large human repert oire antibody libraries. J. Immunol. Methods 391(1-2), 60-71 (2013).
178. Ravn U, Didelot G, Venet Set al. Deep sequencing of phage display libraries to support antibody discovery. Methods 60(1), 99-110 (2013).
179. Nishimura Y, Mieda H, Ishii J, Ogino C, Fujiwara T, Kondo A. Targeting cancer cell-specific RNA interference by SIRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes. J. Nanobiotechnol. 11(19), 1477-3155 (2013).
180. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumo r lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279(52), 53907-53914 (2004).
181. Hatakeyama S, Sugihara K, Shibata TK et al. Targeted drug delivery to tumor vascula ture by a carbohydrate mimetic peptide. Proc. Natl Acad. Sci. USA 108(49), 19587-19592 (2011).
182. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380 (1998).
183. Wang X, Ramstrom O, Yan M. Glyconanomaterials: Synthesis, characterization, and ligand presentation. Adv. Mater. 22(17), 1946-1953 (2010).
184. Jayaraman N. Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions. Chem. Soc. Rev. 38(12), 3463-3483 (2009).
185. Thoma G, Duthaler RO, Magnani JL, Patton JT. Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation. J. Am. Chem. Soc. 123(41), 10113-10114 (2001).
186. Schneider R, Schmitt F, Frochot C et al. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg. Med. Chem. 13(8), 2799-2808 (2005).
187. Sengupta S, Kulkarni A. Design principles for clinical efficacy of cancer nanomedicine: A look into the basics. ACS Nano 7(4), 2878-2882 (2013).
188. Leamon CP, Reddy JA, Klein PJ et al. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J. Pharmacol. Exp. Ther. 336(2), 336-343 (2011).
189. Shiyama T, Furuya M, Yamazaki A, Terada T, Tanaka A. Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resi ns. Bioorg. Med. Chem. 12(11), 2831-2841 (2004).
190. Ueda M, Manabe Y, Mukai M. The high performance of 3XFLAG for target purification of a bioactive metabolite: A tag combined with a highly effectiv e linker structure. Bioorg. Med. Chem. Lett. 21(5), 1359-1362 (2011).
191. Hashimoto M, Yang J, Holman GD. Cell-surface recognition of biotinylated membrane proteins requires very long spacer arms: An example from glucose-transporter probes. Chembiochem 2(1), 52-59 (2001).
192. Sato S, Kwon Y, Kamisuki Set al. Polyproline-rod approach to isolating protein targets of bioactive small mol ecules: Isolation of a new target of indomethacin. J. Am. Chem. Soc. 129(4), 873-880 (2007).
193. Schulz F, Vossmeyer T, Bastus NG, Weller H. Effect of the spacer structure on the stability of gol d nanoparticles functionalized with monodentate thiolated poly(ethylene glycol) ligands. Langmuir 29(31), 9897-9908 (2013).
194. Thielbeer F, Johansson EM, Chankeshwara SV, Bradley M. Influ ence of spacer length on the cellular uptake of polymeric nanoparticles. Macromol. Biosci. 13(6), 682-686 (2013).
195. Tamura S, Inomata S, Ebine Met al. Triazoyl-phenyl linker system enhancing the aqueous solubility of a molecular probe and its efficiency in affinity labeling of a target protein for jasmonate glucoside. Bioorg. Med. Chem. Lett. 23(1), 188-193 (2013).
196. Kaewsaneha C, Opaprakasi t P, Polpanich D, Smanmoo S, Tangboriboonrat P. Immobilization of fluorescein isothiocyanate on magnetic polymeric nanoparticle using chitosan as spacer. J. Colloid Interface Sci. 377(1), 145-152 (2012).
197. Barchanski A, Hashimoto N, Petersen S, Sajti CL, Barcikowski S. Impact of spacer and strand length on oligonucleotide conjugation to the surface of ligand-free laser-generated gold nanoparticles. Bioconjug. Chem. 27, 27 (2012).
198. Weissleder R. Scaling down imaging: Molecular mapping of cancer in mice. Nat. Rev. Cancer 2(1), 11-18 (2002).
199. Tang B, Yu F, Li P et al. A near-infrared neutral pH fluorescent probe for monitoring minor pH changes: Imaging in living HepG2 and HL-7702 cells. J. Am. Chem. Soc. 131(8), 3016-3023 (2009).
200. Ogawa M, Regino CA, Choyke P L, Kobayashi H. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol. Cancer Ther. 8(1), 232-239 (2009).
201. Oga wa M, Kosaka N, Regino CA, Mitsunaga M, Choyke PL, Kobayashi H. High sensitivity detection of cancer in vivo using a dual-controlled activation fluorescent imaging probe based on H-dimer formation and pH activation. Mol. Biosyst. 6(5), 888-893 (2010).
202. Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer met astases. Mol. Pharm. 6(2), 386-395 (2009).
203. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 69(4), 1268-1272 (2009).
204. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. H-type dimer formation of fluorophores: A mechanism for activatabl e, in vivo optical molecular imaging. ACS Chem. Biol. 4(7), 535-546 (2009).
205. Lee S, Xie J, Chen X. Activatable molecular probes for cancer imaging. Curr. Top. Med. Chem. 10(11), 1135-1144 (2010).
206. Lee S, Park K, Kim K, Choi K, Kwon IC. Activatable imaging probes with amplified fluorescent signals. Chem. Commun. 28(36), 4250-4260 (2008).
207. Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: Rational design and in vivo applications. Acc. Chem. Res. 44(2), 83-90 (2011).
208. Gompels LL, Lim NH, Vincent T, Paleolog EM. In vivo optical imaging in arthritis-an enlightening future Rheumatology 49(8), 1436-1446 (2010).
209. Zhou K, Liu H, Z hang Set al. Multicolored pH-tunable and activatable fluorescence nanoplatform responsive to physiologic pH stimuli. J. Am. Chem. Soc. 134(18), 7803-7811 (2012).
210. Weissleder R. A clearer vision for in vivo imaging. Nat. Biotechnol. (19), 316-317 (2001).
211. Mitchell P. Turning the spotlight on cellular imaging. Nat. Biotechnol. 19(11), 1013-1017 (2001).
212. Lacivita E, Leopoldo M, Berardi F, Colabufo NA, Perrone R. Activatable fluorescent probes: A new concept in optical molecular imaging. Curr. Med. Chem. 19(28), 4731-4741 (2012).
213. Cuneo K C, Mito JK, Javid MP et al. Imaging primary mouse sarcomas after radiation therapy using cathepsin-activatable fluorescent imaging agents. Int. J. Radiat. Oncol. Biol. Phys. 86(1), 136-142 (2013).
214. Chevalier A, Massif C, Renard PY, Romieu A. Bioconjugatable azo-based dark-quencher dyes: Synthesis and application to protease-activatable far-red fluorescent probes. Chemistry 19(5), 1686-1699 (2013).
215. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
216. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54(13), 3352-3356 (1994).
217. Jain RK. Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene expression and function. J. Control. Release 74(1-3), 7-25 (2001).
218. Hrkach J, Von Hoff D, Ali MM et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128-139 (2012).
219. Senzer NN, Matsuno K, Yamagata N et al. Abstract C36: MBP-426, a novel liposome-encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): Phase I results of a Phase I/II study in gastro-esophageal adenocarcinoma, with pharmacokinetics. Mol. Cancer Ther. 8(12 Suppl.), C36 (2009).
220. Senzer N, Nemunaitis J, Nemunaitis D et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 21(5), 1096-1103 (2013).
221. Davis ME. The first targeted delivery of SIRNA in humans via a self-assembling, cyclodextrin polymer-based nano particle: From concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
222. Gordon EM, Hall FL. The ?timely?development of Rexin-G: First targeted injectable gene vector (review). Int. J. Oncol. 3 5(2), 229-238 (2009).
223. Seymour LW, Ferry DR, Anderson D et al. Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20(6), 1668-1676 (2002).
224. Matsumura Y, Gotoh M, Muro K et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15(3), 517-525 (2004).